MDMA-Assisted Therapy After the Rejection: Where the Work Stands

Post-traumatic stress disorder has two approved drug treatments in the United States, both selective serotonin reuptake inhibitors, both approved in the early 2000s, and both modest. Sertraline and paroxetine help some people somewhat. A substantial fraction of patients — particularly those with severe, chronic, or combat-related PTSD — do not respond to either, and the field has waited two decades for something else.

That is the backdrop against which MDMA-assisted therapy has been read, and it explains a great deal about how the results were received.

What the trials found

The Phase 3 programme run by MAPS, later through its corporate arm Lykos Therapeutics, tested MDMA administered across a small number of supervised sessions, each lasting several hours, embedded in a course of preparatory and integrative psychotherapy with two therapists present throughout.

The headline numbers were unusual. Across the Phase 3 work, roughly two-thirds of participants no longer met diagnostic criteria for PTSD after three sessions, and follow-up data suggested the improvement largely held over subsequent years rather than decaying in the way that acute drug effects often do.

Effect sizes of that magnitude are rare in psychiatry. They are also, precisely because they are rare, the point at which a careful reader should start asking how the trial was run.

What the FDA actually objected to

In June 2024, an FDA advisory committee voted decisively against the application — against efficacy, and more heavily against the benefit-risk balance. In August 2024 the agency issued a complete response letter to Lykos, declining approval and requesting an additional Phase 3 trial.

The objections clustered around trial conduct rather than around whether MDMA does something.

The most serious was functional unblinding. MDMA at active doses is unmistakable. Participants knew what they had received, therapists knew, and in a trial where the primary outcome is a clinician-administered symptom rating, that knowledge contaminates the measurement at both ends. This is a hard problem for the whole psychedelic field, not a lapse specific to one sponsor, but it is not solved by pointing that out.

Beyond blinding, the committee raised the difficulty of separating drug effect from therapy effect when the two are bundled into a single intervention the agency does not have a framework to regulate; questions about how adverse events, including abuse potential and cardiovascular effects, had been collected and reported; and conduct allegations arising from the trial programme.

The application was not rejected because the drug did nothing. It was rejected because the trial could not rule out the alternative explanations.

Where the work sits now

Research did not stop. Trials continue, including work supported through defence and veterans' health channels, where the population most affected by treatment-resistant PTSD is concentrated and the institutional appetite for an alternative is highest. New academic trials have opened, among them work testing MDMA alongside massed exposure therapy — an approach that compresses a standard evidence-based PTSD treatment into a short intensive course, and which has the advantage of an established comparator.

That last design choice is the interesting one. It points at what the next generation of trials has to do: compare MDMA-assisted therapy not against a placebo that everyone can see through, but against an active psychotherapy of comparable intensity, so that the question being answered is whether the drug adds something to good trauma treatment rather than whether good trauma treatment beats nothing.

What a reader should take from this

MDMA remains a Schedule I substance in the United States and is not an approved treatment. Ketamine and esketamine remain the only rapid-acting pharmacological options available through conventional psychiatric care, and they are approved for depression rather than PTSD.

The honest description of the evidence is that the signal is large, the design was not strong enough to attribute it confidently, and the regulator asked for the trial that would settle it. Those three statements are compatible with each other. Anyone presenting the rejection as proof the therapy does not work, or as purely political obstruction, is choosing one of them and discarding the rest.

This article is general information, not medical advice. See our Editorial Standards.